238 related articles for article (PubMed ID: 31668005)
1. Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasis.
El-Naggar AM; Somasekharan SP; Wang Y; Cheng H; Negri GL; Pan M; Wang XQ; Delaidelli A; Rafn B; Cran J; Zhang F; Zhang H; Colborne S; Gleave M; Mandinova A; Kedersha N; Hughes CS; Surdez D; Delattre O; Wang Y; Huntsman DG; Morin GB; Sorensen PH
EMBO Rep; 2019 Dec; 20(12):e48375. PubMed ID: 31668005
[TBL] [Abstract][Full Text] [Related]
2. Panobinostat-A Potential Treatment for Metastasized Ewing Sarcoma? A Case Report.
van Maldegem AM; Bovée JV; Gelderblom H
Pediatr Blood Cancer; 2016 Oct; 63(10):1840-3. PubMed ID: 27245095
[TBL] [Abstract][Full Text] [Related]
3. Translational Activation of HIF1α by YB-1 Promotes Sarcoma Metastasis.
El-Naggar AM; Veinotte CJ; Cheng H; Grunewald TG; Negri GL; Somasekharan SP; Corkery DP; Tirode F; Mathers J; Khan D; Kyle AH; Baker JH; LePard NE; McKinney S; Hajee S; Bosiljcic M; Leprivier G; Tognon CE; Minchinton AI; Bennewith KL; Delattre O; Wang Y; Dellaire G; Berman JN; Sorensen PH
Cancer Cell; 2015 May; 27(5):682-97. PubMed ID: 25965573
[TBL] [Abstract][Full Text] [Related]
4. The Nephroprotective Effect of MS-275 on Lipopolysaccharide (LPS)-Induced Acute Kidney Injury by Inhibiting Reactive Oxygen Species (ROS)-Oxidative Stress and Endoplasmic Reticulum Stress.
Zhang H; Zhang W; Jiao F; Li X; Zhang H; Wang L; Gong Z
Med Sci Monit; 2018 Apr; 24():2620-2630. PubMed ID: 29704392
[TBL] [Abstract][Full Text] [Related]
5. YB-1 regulates stress granule formation and tumor progression by translationally activating G3BP1.
Somasekharan SP; El-Naggar A; Leprivier G; Cheng H; Hajee S; Grunewald TG; Zhang F; Ng T; Delattre O; Evdokimova V; Wang Y; Gleave M; Sorensen PH
J Cell Biol; 2015 Mar; 208(7):913-29. PubMed ID: 25800057
[TBL] [Abstract][Full Text] [Related]
6. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells.
Sonnemann J; Dreyer L; Hartwig M; Palani CD; Hong le TT; Klier U; Bröker B; Völker U; Beck JF
J Cancer Res Clin Oncol; 2007 Nov; 133(11):847-58. PubMed ID: 17486365
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoid receptor signaling represses the antioxidant response by inhibiting histone acetylation mediated by the transcriptional activator NRF2.
Alam MM; Okazaki K; Nguyen LTT; Ota N; Kitamura H; Murakami S; Shima H; Igarashi K; Sekine H; Motohashi H
J Biol Chem; 2017 May; 292(18):7519-7530. PubMed ID: 28314773
[TBL] [Abstract][Full Text] [Related]
9. Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines.
Welch D; Kahen E; Fridley B; Brohl AS; Cubitt CL; Reed DR
PLoS One; 2019; 14(9):e0222228. PubMed ID: 31550266
[TBL] [Abstract][Full Text] [Related]
10. IGF-1R/MDM2 relationship confers enhanced sensitivity to RITA in Ewing sarcoma cells.
Di Conza G; Buttarelli M; Monti O; Pellegrino M; Mancini F; Pontecorvi A; Scotlandi K; Moretti F
Mol Cancer Ther; 2012 Jun; 11(6):1247-56. PubMed ID: 22461661
[TBL] [Abstract][Full Text] [Related]
11. MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent.
Hess-Stumpp H; Bracker TU; Henderson D; Politz O
Int J Biochem Cell Biol; 2007; 39(7-8):1388-405. PubMed ID: 17383217
[TBL] [Abstract][Full Text] [Related]
12. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo.
Srivastava RK; Kurzrock R; Shankar S
Mol Cancer Ther; 2010 Dec; 9(12):3254-66. PubMed ID: 21041383
[TBL] [Abstract][Full Text] [Related]
13. Menin regulates the serine biosynthetic pathway in Ewing sarcoma.
Svoboda LK; Teh SSK; Sud S; Kerk S; Zebolsky A; Treichel S; Thomas D; Halbrook CJ; Lee HJ; Kremer D; Zhang L; Klossowski S; Bankhead AR; Magnuson B; Ljungman M; Cierpicki T; Grembecka J; Lyssiotis CA; Lawlor ER
J Pathol; 2018 Jul; 245(3):324-336. PubMed ID: 29672864
[TBL] [Abstract][Full Text] [Related]
14. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.
Dai Y; Rahmani M; Dent P; Grant S
Mol Cell Biol; 2005 Jul; 25(13):5429-44. PubMed ID: 15964800
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide inhibits Ewing's sarcoma cell invasiveness by targeting p38(MAPK) and c-Jun N-terminal kinase.
Zhang S; Guo W; Ren TT; Lu XC; Tang GQ; Zhao FL
Anticancer Drugs; 2012 Jan; 23(1):108-18. PubMed ID: 21946058
[TBL] [Abstract][Full Text] [Related]
16. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
17. DNA methylation profiling opens a new phase in the search of targeted therapy against Ewing sarcoma.
Rello-Varona S; Tirado OM
Pharmacogenomics; 2017 Sep; 18(14):1307-1309. PubMed ID: 28832268
[No Abstract] [Full Text] [Related]
18. Modeling Stroma-Induced Drug Resistance in a Tissue-Engineered Tumor Model of Ewing Sarcoma.
Santoro M; Menegaz BA; Lamhamedi-Cherradi SE; Molina ER; Wu D; Priebe W; Ludwig JA; Mikos AG
Tissue Eng Part A; 2017 Jan; 23(1-2):80-89. PubMed ID: 27923328
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
Theisen ER; Pishas KI; Saund RS; Lessnick SL
Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
[TBL] [Abstract][Full Text] [Related]
20. Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways.
Sampson VB; Vetter NS; Kamara DF; Collier AB; Gresh RC; Kolb EA
PLoS One; 2015; 10(11):e0142704. PubMed ID: 26571493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
